Core Viewpoint - DURECT Corporation has sold its ALZET® line of osmotic pumps to Lafayette Instrument Co. for $17.5 million, allowing the company to focus on its lead drug candidate, larsucosterol, and strengthen its financial position [1][2][3]. Financial Transaction - Lafayette Instrument Co. paid DURECT $17.5 million for certain assets and liabilities associated with the ALZET product line [2]. - The transaction enabled DURECT to pay off all remaining obligations under its term loan agreement with Oxford Finance LLC, enhancing its financial flexibility [2][3]. Strategic Focus - DURECT is prioritizing the development of larsucosterol for alcohol-associated hepatitis (AH) and has determined that the ALZET product line no longer aligns with its long-term strategic priorities [3]. - The sale strengthens DURECT's cash position and extends its cash runway through the first half of 2025, which is crucial for funding the planned Phase 3 clinical trial for larsucosterol [3]. Product Information - The ALZET product line consists of miniature, implantable osmotic pumps designed for research use in laboratory animals, capable of delivering drugs and hormones at controlled rates [5]. - These pumps have been referenced in over 22,000 published scientific studies, indicating their wide application in laboratory research [5]. Company Overview - DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies for serious conditions, including acute organ injury [6]. - Larsucosterol, the company's lead drug candidate, is in clinical development for the treatment of AH and has received Fast Track and Breakthrough Therapy designations from the FDA [6].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of inc ...

DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings! And welcome to the DURECT Corporation Third Quarter 2024 Earnings Conference Call. At th ...

Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.65%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.17 per share when it actually produced a loss of $0.12, delivering a surprise of 29.41%.Over the last four quarters, the comp ...

Exhibit 99.1 DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., November 13, 2024 /PRNewswire / -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. "We remain foc ...

-     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation-     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ETCUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update."We remain focused on preparations for the Phase 3 trial for larsucosterol in severe alcohol-associated hepatitis (AH), ...

CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate ...

CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California. The ...

- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO ...

CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York City. Management will also be available for virtual 1×1 meetings from Septe ...